Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia

References

Altman, J.K., Daver, N., Maly, J., Levis, M., Ritchie, E., Litzow, M., McCloskey, J., Smith, C.C., Schiller, G., Bradley, T., et al. (2021). AML-162: efficacy and safety of venetoclax in combination with gilteritinib for relapsed/refractory FLT3-mutated acute myeloid leukemia: updated analyses of a phase 1b study. Clin. Lymphoma Myeloma Leuk. 21: S285.10.1016/S2152-2650(21)01684-0Search in Google Scholar

Amadori, S., Venditti, A., Voso, M.T., Annino, L., De Fabritiis, P., Alimena, G., Mancini, M., Paoloni, F., Vignetti, M., Fazi, P., et al. (2016). Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J. Clin. Oncol. 34: 972–979.10.1200/JCO.2015.64.0060Search in Google Scholar PubMed

Bogenberger, J.M., Kornblau, S.M., Pierceall, W.E., Lena, R., Chow, D., Shi, C.X., Mantei, J., Ahmann, G., Gonzales, I.M., Choudhary, A., et al. (2014). BCL-2 family proteins as 5-azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 28: 1657–1665.10.1038/leu.2014.44Search in Google Scholar PubMed PubMed Central

Andreeff, M., Jiang, S., Zhang, X., Konopleva, M., Estrov, Z., Snell, V.E., Xie, Z., Okcu, M.F., Sanchez-Williams, G., Dong, J., et al. (1999). Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid, in leukemia. Nature 13: 1881–1892.10.1038/sj.leu.2401573Search in Google Scholar PubMed

Bhatt, S., Pioso, M.S., Olesinski, E.A., Yilma, B., Ryan, J.A., Mashaka, T., Leutz, B., Adamia, S., Zhu, H., Kuang, Y., et al. (2020). Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell 38: 872–890.10.1016/j.ccell.2020.10.010Search in Google Scholar PubMed PubMed Central

Bogenberger, J.M., Delman, D., Hansen, N., Valdez, R., Fauble, V., Mesa, R.A., and Tibes, R. (2015). Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk. Lymphoma 56: 226–229.10.3109/10428194.2014.910657Search in Google Scholar PubMed PubMed Central

Caenepeel, S., Brown, S.P., Belmontes, B., Moody, G., Keegan, K.S., Chui, D., Whittington, D.A., Huang, X., Poppe, L., Cheng, A.C., et al. (2018). AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 8: 1582–1597.10.1158/2159-8290.CD-18-0387Search in Google Scholar

Campos, L., Rouault, J.P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J.P., and Guyotat, D. (1993). High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091–3096.10.1182/blood.V81.11.3091.3091Search in Google Scholar

Cancer Genome Atlas Research Network (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368: 2059–2074.10.1056/NEJMoa1301689Search in Google Scholar PubMed PubMed Central

Caprioli, C., Lussana, F., Salmoiraghi, S., Cavagna, R., Buklijas, K., Elidi, L., Zanghi’, P., Michelato, A., Delaini, F., Oldani, E., et al. (2020). Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. Haematologica 106: 2578–2587.10.3324/haematol.2020.252825Search in Google Scholar PubMed PubMed Central

Cathelin, S., Sharon, D., Subedi, A., Cojocari, D., Phillips, D.C., Leverson, J.D., MacBeth, K., Nicolay, B., Narayanaswamy, R., Ronseaux, S., et al. (2018). Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models. Blood 132: 562.10.1182/blood-2018-99-119688Search in Google Scholar

Certo, M., Moore, V.D.G., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S.A., and Letai, A. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351–365.10.1016/j.ccr.2006.03.027Search in Google Scholar

Chan, S.M., Thomas, D., Corces-Zimmerman, M.R., Xavy, S., Rastogi, S., Hong, W.J., Zhao, F., Medeiros, B.C., Tyvoll, D.A., and Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21: 178–184.10.1038/nm.3788Search in Google Scholar

Chen, L., Willis, S.N., Wei, A., Smith, B.J., Fletcher, J.I., Hinds, M.G., Colman, P.M., Day, C.L., Adams, J.M., and Huang, D.C.S. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell. 17: 393–403.10.1016/j.molcel.2004.12.030Search in Google Scholar

Cheng, E.H.Y., Wei, M.C., Weiler, S., Flavell, R.A., Mak, T.W., Lindsten, T., and Korsmeyer, S.J. (2001). BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8: 705–711.10.1016/S1097-2765(01)00320-3Search in Google Scholar

Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., Newmeyer, D.D., Schuler, M., and Green, D.R. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303: 1010–1014.10.1126/science.1092734Search in Google Scholar PubMed

Chonghaile, T.N., Sarosiek, K.A., Vo, T.T., Ryan, J.A., Tammareddi, A., Moore, V.D.G., Deng, J., Anderson, K.C., Richardson, P., Tai, Y.T., et al. (2011). Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334: 1129–1133.10.1126/science.1206727Search in Google Scholar PubMed PubMed Central

Chua, C.C., Roberts, A.W., Reynolds, J., Fong, C.Y., Ting, S.B., Salmon, J.M., MacRaild, S., Ivey, A., Tiong, I.S., Fleming, S., et al. (2020). Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J. Clin. Oncol. 38: 3506–3517.10.1200/JCO.20.00572Search in Google Scholar PubMed

Chyla, B., Daver, N., Doyle, K., McKeegan, E., Huang, X., Ruvolo, V., Wang, Z., Chen, K., Souers, A., Leverson, J., et al. (2018). Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. Am. J. Hematol. 93: E202–E205.10.1002/ajh.25146Search in Google Scholar PubMed PubMed Central

Claus, R. and Lübbert, M. (2003). Epigenetic targets in hematopoietic malignancies. Oncogene 22: 6489–6496.10.1038/sj.onc.1206814Search in Google Scholar PubMed

Cluzeau, T., Sebert, M., Rahmé, R., Cuzzubbo, S., Walter-petrich, A., Lehmannche, J., Peterlin, P., Beve, B., Attalah, H., Chermat, F., et al. (2019). APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A phase 2 study by the groupe francophone des myélodysplasies (GFM). Blood 134: 677.10.1182/blood-2019-125579Search in Google Scholar

Constantinides, P.G., Jones, P.A., and Gevers, W. (1977). Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267: 364–366.10.1038/267364a0Search in Google Scholar

DiNardo, C.D., Pratz, K., Pullarkat, V., Jonas, B.A., Arellano, M., Becker, P.S., Frankfurt, O., Konopleva, M., Wei, A.H., Kantarjian, H.M., et al. (2019). Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133: 7–17.10.1182/blood-2018-08-868752Search in Google Scholar

DiNardo, C.D., Maiti, A., Rausch, C.R., Pemmaraju, N., Naqvi, K., Daver, N.G., Kadia, T.M., Borthakur, G., Ohanian, M., Alvarado, Y., et al. (2020a). 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 7: e724–e736.10.1016/S2352-3026(20)30210-6Search in Google Scholar

Cortes, J.E., Heidel, F.H., Hellmann, A., Fiedler, W., Smith, B.D., Robak, T., Montesinos, P., Pollyea, D.A., DesJardins, P., Ottmann, O., et al. (2019). Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33: 379–389.10.1038/s41375-018-0312-9Search in Google Scholar PubMed PubMed Central

Crews, L.A., Balaian, L., Delos Santos, N.P., Leu, H.S., Court, A.C., Lazzari, E., Sadarangani, A., Zipeto, M.A., La Clair, J.J., Villa, R., et al. (2016). RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML. Cell Stem Cell 19: 599–612.10.1016/j.stem.2016.08.003Search in Google Scholar PubMed PubMed Central

Czabotar, P.E., Westphal, D., Dewson, G., Ma, S., Hockings, C., Fairlie, W.D., Lee, E.F., Yao, S., Robin, A.Y., Smith, B.J., et al. (2013). Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152: 519–531.10.1016/j.cell.2012.12.031Search in Google Scholar PubMed

Dariushnejad, H., Zarghami, N., Rahmati, M., Ghasemali, S., Sadeghi, Z., Davoodi, Z., Tekab, H.J., and Ghalhar, M.G. (2014). ABT-737, synergistically enhances daunorubicin-mediated apoptosis in acute myeloid leukemia cell lines. Adv. Pharm. Bull. 4: 185.Search in Google Scholar

DiNardo, C.D., Jonas, B.A., Pullarkat, V., Thirman, M.J., Garcia, J.S., Wei, A.H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020b). Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383: 617–629.10.1056/NEJMoa2012971Search in Google Scholar PubMed

DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R., Collins, R.H., Mannis, G.N., Pollyea, D.A., et al. (2018). Durable remissions with ivosidenib in IDH1 -mutated relapsed or refractory AML. N. Engl. J. Med. 378: 2386–2398.10.1056/NEJMoa1716984Search in Google Scholar PubMed

DiNardo, C.D., Tiong, I.S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F.C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J.M., et al. (2020c). Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135: 791–803.10.1182/blood.2019003988Search in Google Scholar PubMed PubMed Central

Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F.R., Büchner, T., Dombret, H., Ebert, B.L., Fenaux, P., Larson, R.A., et al. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129: 424–447.10.1182/blood-2016-08-733196Search in Google Scholar PubMed PubMed Central

Döhner, H., Weisdorf, D.J., and Bloomfield, C.D. (2015). Acute myeloid leukemia. N. Engl. J. Med. 373: 1136–1152.10.1056/NEJMra1406184Search in Google Scholar

Dombret, H., Seymour, J.F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J.H., Kumar, R., Cavenagh, J., Schuh, A.C., Candoni, A., et al. (2015). International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126: 291–299.10.1182/blood-2015-01-621664Search in Google Scholar

Dzhagalov, I., St. John, A., and He, Y.W. (2007). The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 109: 1620–1626.10.1182/blood-2006-03-013771Search in Google Scholar

Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10: 223–232.10.1016/S1470-2045(09)70003-8Search in Google Scholar

Fenaux, P., Mufti, G.J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A.F., Gore, S., Seymour, J.F., et al. (2010). Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J. Clin. Oncol. 28: 562–569.10.1200/JCO.2009.23.8329Search in Google Scholar

Garcia-Manero, G., McCloskey, J., Griffiths, E.A., Yee, K.W.L., Zeidan, A.M., Al-Kali, A., Dao, K.-H., Deeg, H.J., Patel, P.A., Sabloff, M., et al. (2019). Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine/decitabine) compared to IV decitabine. Blood 134: 846.10.1182/blood-2019-122980Search in Google Scholar

Gawlitza, A.L., Speith, J., Rinke, J., Sajzew, R., Müller, E.K., Schäfer, V., Hochhaus, A., and Ernst, T. (2019). 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes. J. Cancer Res. Clin. Oncol. 145: 2835–2843.10.1007/s00432-019-03016-9Search in Google Scholar

Hollenbach, P.W., Nguyen, A.N., Brady, H., Williams, M., Ning, Y., Richard, N., Krushel, L., Aukerman, S.L., Heise, C., and MacBeth, K.J. (2010). A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5: e9001.10.1371/journal.pone.0009001Search in Google Scholar

Hunter, A.M. and Sallman, D.A. (2019). Current status and new treatment approaches in TP53 mutated AML. Best Pract. Res. Clin. Haematol. 32: 134–144.10.1016/j.beha.2019.05.004Search in Google Scholar

Issa, J.P.J., Roboz, G., Rizzieri, D., Jabbour, E., Stock, W., O’Connell, C., Yee, K., Tibes, R., Griffiths, E.A., Walsh, K., et al. (2015). Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 16: 1099–1110.10.1016/S1470-2045(15)00038-8Search in Google Scholar

Jin, S., Cojocari, D., Purkal, J.J., Popovic, R., Talaty, N.N., Xiao, Y., Solomon, L.R., Boghaert, E.R., Leverson, J.D., and Phillips, D.C. (2020). 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin. Cancer Res. 26: 3371–3383.10.1158/1078-0432.CCR-19-1900Search in Google Scholar

Jones, P.A. and Baylin, S.B. (2002). The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415–428.10.1038/nrg816Search in Google Scholar

Jones, P.A. and Taylor, S.M. (1980). Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85–93.10.1016/0092-8674(80)90237-8Search in Google Scholar

Kale, J., Osterlund, E.J., and Andrews, D.W. (2017). BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25: 65–80.10.1038/cdd.2017.186Search in Google Scholar

Kantarjian, H., Ravandi, F., O’Brien, S., Cortes, J., Faderl, S., Garcia-Manero, G., Jabbour, E., Wierda, W., Kadia, T., Pierce, S., et al. (2010). Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116: 4422–4429.10.1182/blood-2010-03-276485Search in Google Scholar

Karakas, T., Maurer, U., Weidmann, E., Miething, C.C., Hoelzer, D., and Bergmann, L. (1998). High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 9: 159–165.10.1023/A:1008255511404Search in Google Scholar

Kasper, S., Breitenbuecher, F., Heidel, F., Hoffarth, S., Markova, B., Schuler, M., and Fischer, T. (2012). Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J. 2: e60, doi:https://doi.org/10.1038/bcj.2012.5.10.1038/bcj.2012.5Search in Google Scholar

Kim, Y.H., Park, J.W., Lee, J.Y., Surh, Y.J., and Kwon, T.K. (2003). Bcl-2 overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP and Akt degradation. Biochem. Pharmacol. 66: 1779–1786.10.1016/S0006-2952(03)00545-8Search in Google Scholar

Konopleva, M., Pollyea, D.A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A.H., Zhu, M., Ricker, J.L., et al. (2016). Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6: 1106–1117.10.1158/2159-8290.CD-16-0313Search in Google Scholar PubMed PubMed Central

Krug, U., Büchner, T., Berdel, W.E., and Müller-Tidow, C. (2011). The treatment of elderly patients with acute myeloid leukemia. Dtsch. Arztebl. Int. 108: 863–870.10.3238/arztebl.2011.0863Search in Google Scholar PubMed PubMed Central

Kuykendall, J.R. (2005). 5-Azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann. Pharmacother. 39: 1700–1709.10.1345/aph.1E612Search in Google Scholar

Lachowiez, C.A., Loghavi, S., Kadia, T.M., Daver, N., Borthakur, G., Pemmaraju, N., Naqvi, K., Alvarado, Y., Yilmaz, M., Short, N., et al. (2020a). Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 4: 1311–1320.10.1182/bloodadvances.2019001267Search in Google Scholar

Lachowiez, C.A., Borthakur, G., Loghavi, S., Zeng, Z., Kadia, T.M., Masarova, L., Takahashi, K., Tippett, G.D., Naqvi, K., Bose, P., et al. (2020b). Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. J. Clin. Oncol. 38: 7500.10.1200/JCO.2020.38.15_suppl.7500Search in Google Scholar

Lachowiez, C.A., Loghavi, S., Furudate, K., Montalban-Bravo, G., Maiti, A., Kadia, T., Daver, N., Borthakur, G., Pemmaraju, N., Sasaki, K., et al. (2021). Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 5: 2173–2183.10.1182/bloodadvances.2020004173Search in Google Scholar

Lambert, J., Pautas, C., Terré, C., Raffoux, E., Turlure, P., Caillot, D., Legrand, O., Thomas, X., Gardin, C., Gogat-Marchant, K., et al. (2019). Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104: 113–119.10.3324/haematol.2018.188888Search in Google Scholar

Latini, A., Da Silva, C.G., Ferreira, G.C., Schuck, P.F., Scussiato, K., Sarkis, J.J., Dutra Filho, C.S., Wyse, A.T.S., Wannmacher, C.M.D., and Wajner, M. (2005). Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues. Mol. Genet. Metabol. 86: 188–199.10.1016/j.ymgme.2005.05.002Search in Google Scholar

Leber, B., Lin, J., and Andrews, D.W. (2007). Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 12: 897–911.10.1007/s10495-007-0746-4Search in Google Scholar

Leber, B., Lin, J., and Andrews, D.W. (2010). Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene 29: 5221–5230.10.1038/onc.2010.283Search in Google Scholar

Lee, T.T. and Karon, M.R. (1976). Inhibition of protein synthesis in 5-azacytidine-treated HeLa cells. Biochem. Pharmacol. 25: 1737–1742.10.1016/0006-2952(76)90407-XSearch in Google Scholar

Lessene, G., Czabotar, P.E., and Colman, P.M. (2008). BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7: 989–1000.10.1038/nrd2658Search in Google Scholar PubMed

Li, L., Bailey, E., Greenblatt, S., Huso, D., and Small, D. (2011). Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice. Blood 118: 4935–4945.10.1182/blood-2011-01-328096Search in Google Scholar PubMed PubMed Central

Ma, J., Zhao, S., Qiao, X., Knight, T., Edwards, H., Polin, L., Kushner, J., Dzinic, S.H., White, K., Wang, G., et al. (2019). Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin. Cancer Res. 25: 6815–6826.10.1158/1078-0432.CCR-19-0832Search in Google Scholar PubMed PubMed Central

Maiti, A., DiNardo, C.D., Daver, N.G., Rausch, C.R., Ravandi, F., Kadia, T.M., Pemmaraju, N., Borthakur, G., Bose, P., Issa, G.C., et al. (2021). Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 11: 1–6.10.1038/s41408-021-00410-wSearch in Google Scholar PubMed PubMed Central

Mali, R.S., Zhang, Q., DeFilippis, R., Cavazos, A., Kuruvilla, V.M., Raman, J., Mody, V., Choo, E.F., Dail, M., Shah, N.P., et al. (2021). Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica 106: 1034–1046.10.3324/haematol.2019.244020Search in Google Scholar PubMed PubMed Central

McGhee, J.D. and Ginder, G.D. (1979). Specific DNA methylation sites in the vicinity of the chicken β-globin genes. Nature 280: 419–420.10.1038/280419a0Search in Google Scholar PubMed

Meldi, K., Qin, T., Buchi, F., Droin, N., Sotzen, J., Micol, J.B., Selimoglu-Buet, D., Masala, E., Allione, B., Gioia, D., et al. (2015). Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J. Clin. Invest. 125: 1857–1872.10.1172/JCI78752Search in Google Scholar PubMed PubMed Central

Montero, J., Sarosiek, K.A., Deangelo, J.D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N.S., Berkowitz, R.S., Matulonis, U., et al. (2015). Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160: 977–989.10.1016/j.cell.2015.01.042Search in Google Scholar PubMed PubMed Central

Morita, K., Wang, F., Jahn, K., Hu, T., Tanaka, T., Sasaki, Y., Kuipers, J., Loghavi, S., Wang, S.A., Yan, Y., et al. (2020). Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11: 1–17.10.1038/s41467-020-19119-8Search in Google Scholar

Nagel, G., Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., Kündgen, A., et al. (2017). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann. Hematol. 96: 1993–2003.10.1007/s00277-017-3150-3Search in Google Scholar PubMed PubMed Central

Nechiporuk, T., Kurtz, S.E., Nikolova, O., Liu, T., Jones, C.L., D’Alessandro, A., Culp-Hill, R., d’Almeida, A., Joshi, S.K., Rosenberg, M., et al. (2019). The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 9: 910–925.10.1158/2159-8290.CD-19-0125Search in Google Scholar PubMed PubMed Central

Nguyen, M., Marcellus, R.C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S.R., Goulet, D., Viallet, J., Bélec, L., Billot, X., et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U.S.A. 104: 19512–19517.10.1073/pnas.0709443104Search in Google Scholar PubMed PubMed Central

Niu, X., Zhao, J., Ma, J., Xie, C., Edwards, H., Wang, G., Caldwell, J. T., Xiang, S., Zhang, X., Chu, R., et al. (2016). Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin. Cancer Res. 22: 4440–4451.10.1158/1078-0432.CCR-15-3057Search in Google Scholar PubMed PubMed Central

Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J., et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.10.1038/nature03579Search in Google Scholar PubMed

Opferman, J.T. and Kothari, A. (2018). Anti-apoptotic BCL-2 family members in development. Cell Death Differ. 25: 37–45.10.1038/cdd.2017.170Search in Google Scholar PubMed PubMed Central

Orkin, S.H. and Zon, L.I. (2008). Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132: 631–644.10.1016/j.cell.2008.01.025Search in Google Scholar PubMed PubMed Central

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P., Roberts, N.D., Potter, N.E., Heuser, M., Thol, F., Bolli, N., et al. (2016). Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374: 2209–2221.10.1056/NEJMoa1516192Search in Google Scholar PubMed PubMed Central

Peng, X., Zhang, M.Q.Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V.J.N., Arnér, E.S.J., and Wiman, K.G. (2013). APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 4: e881.10.1038/cddis.2013.417Search in Google Scholar PubMed PubMed Central

Perl, A.E., Martinelli, G., Cortes, J.E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M.R., Larson, R.A., Ustun, C., et al. (2019). Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl. J. Med. 381: 1728–1740.10.1056/NEJMoa1902688Search in Google Scholar PubMed

Pettit, K. and Odenike, O. (2015). Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies. Front. Oncol. 5: 280, doi:https://doi.org/10.3389/fonc.2015.00280.Search in Google Scholar PubMed PubMed Central

Platt, M.Y., Fathi, A.T., Borger, D.R., Brunner, A.M., Hasserjian, R.P., Balaj, L., Lum, A., Yip, S., Dias-Santagata, D., Zheng, Z., et al. (2015). Detection of dual IDH1 and IDH2 mutations by targeted next-generation sequencing in acute myeloid leukemia and myelodysplastic syndromes. J. Mol. Diagn. 17: 661–668.10.1016/j.jmoldx.2015.06.004Search in Google Scholar PubMed PubMed Central

Pollyea, D.A., Dinardo, C.D., Arellano, M.L., Pigneux, A., Fiedler, W., Konopleva, M., Rizzieri, D.A., Smith, B.D., Shinagawa, A., Lemoli, R.M., et al. (2020). Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH 1/2 mutations. Blood 136: 5–7.10.1182/blood-2020-134736Search in Google Scholar

Pronier, E. and Levine, R.L. (2015). IDH1/2 mutations and BCL-2 dependence: an unexpected chink in AML’s armour. Cancer Cell 27: 323–325.10.1016/j.ccell.2015.02.013Search in Google Scholar

Qin, T., Castoro, R., El Ahdab, S., Jelinek, J., Wang, X., Si, J., Shu, J., He, R., Zhang, N., Chung, W., et al. (2011). Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 6: e23372.10.1371/journal.pone.0023372Search in Google Scholar

Ramsey, H.E., Fischer, M.A., Lee, T., Gorska, A.E., Arrate, M.P., Fuller, L., Boyd, K.L., Strickland, S.A., Sensintaffar, J., Hogdal, L.J., et al. (2018). A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 8: 1566–1581.10.1158/2159-8290.CD-18-0140Search in Google Scholar

Reyna, D.E., Garner, T.P., Lopez, A., Kopp, F., Choudhary, G.S., Sridharan, A., Narayanagari, S.R., Mitchell, K., Dong, B., Bartholdy, B.A., et al. (2017). Direct activation of BAX by BTSA1 overcomes apoptosis resistance in acute myeloid leukemia. Cancer Cell 32: 490–505.e10.10.1016/j.ccell.2017.09.001Search in Google Scholar

Rivard, G.E., Momparler, R.L., Demers, J., Benoit, P., Raymond, R., Lin, K.T., and Momparler, L.F. (1981). Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk. Res. 5: 453–462.10.1016/0145-2126(81)90116-8Search in Google Scholar

Ryan, J. and Letai, A. (2013). BH3 profiling in whole cells by fluorimeter or FACS. Methods 61: 156–164.10.1016/j.ymeth.2013.04.006Search in Google Scholar

Saiki, J.H., Bodey, G.P., Hewlett, J.S., Amare, M., Morrision, F.S., Wilson, H.E., and Linman, J.W. (1981). Effect of schedule on activity and toxicity of 5‐azacytidine in acute leukemia: a southwest oncology group study. Cancer 47: 1739–1742.10.1002/1097-0142(19810401)47:7<1739::AID-CNCR2820470702>3.0.CO;2-2Search in Google Scholar

Saliba, A.N., John, A.J., and Kaufmann, S.H. (2020). Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. Cancer Drug Resist. 4: 125–142.10.20517/cdr.2020.95Search in Google Scholar

Sallman, D.A., Al Ali, N., Yun, S., Padron, E., Song, J., Hussaini, M.O., Talati, C., Sweet, K.L., Lancet, J.E., List, A.F., et al. (2018). Clonal suppression of TP53 mutant MDS and oligoblastic AML with hypomethylating agent therapy improves overall survival. Blood 132: 1817.10.1182/blood-2018-99-117297Search in Google Scholar

Sallman, D.A., Asch, A.S., Al Malki, M.M., Lee, D.J., Donnellan, W.B., Marcucci, G., Kambhampati, S., Daver, N.G., Garcia-Manero, G., Komrokji, R.S., et al. (2019). The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results. Blood 134: 569.10.1182/blood-2019-126271Search in Google Scholar

Sallman, D.A., DeZern, A.E., Garcia-Manero, G., Steensma, D.P., Roboz, G.J., Sekeres, M.A., Cluzeau, T., Sweet, K.L., McLemore, A., McGraw, K.L., et al. (2021). Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J. Clin. Oncol. 39: 1584–1594.10.1200/JCO.20.02341Search in Google Scholar

Sasaki, K., Kanagal-Shamanna, R., Montalban-Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., et al. (2020). Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer 126: 765–774.10.1002/cncr.32566Search in Google Scholar

Shamas-Din, A., Kale, J., Leber, B., and Andrews, D.W. (2013). Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 5: a008714.10.1101/cshperspect.a008714Search in Google Scholar

Short, N.J., Kantarjian, H.M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T.M., Daver, N., Ohanian, M., Dinardo, C.D., et al. (2019). Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 6: e29–e37.10.1016/S2352-3026(18)30182-0Search in Google Scholar

Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., et al. (2002). Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20: 2429–2440.10.1200/JCO.2002.04.117Search in Google Scholar PubMed

Silverman, L.R., McKenzie, D.R., Peterson, B.L., Holland, J.F., Backstrom, J.T., Beach, C.L., and Larson, R.A. (2006). Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 24: 3895–3903.10.1200/JCO.2005.05.4346Search in Google Scholar PubMed

Singh, R., Letai, A., and Sarosiek, K. (2019). Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20: 175–193.10.1038/s41580-018-0089-8Search in Google Scholar PubMed PubMed Central

Singhal, D., Wee, L.Y.A., Kutyna, M.M., Chhetri, R., Geoghegan, J., Schreiber, A.W., Feng, J., Wang, P.P.S., Babic, M., Parker, W.T., et al. (2019). The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia 33: 2842–2853.10.1038/s41375-019-0479-8Search in Google Scholar PubMed

Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, S.L., Catron, N.D., Chen, J., Dayton, B.D., Ding, H., Enschede, S.H., Fairbrother, W.J., et al. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19: 202–208.10.1038/nm.3048Search in Google Scholar PubMed

Stahl, M., Menghrajani, K., Derkach, A., Chan, A., Xiao, W., Glass, J., King, A.C., Daniyan, A.F., Famulare, C., Cuello, B.M., et al. (2021). Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 5: 1552–1564.10.1182/bloodadvances.2020003734Search in Google Scholar PubMed PubMed Central

Steimer, D.A., Boyd, K., Takeuchi, O., Fisher, J.K., Zambetti, G.P., and Opferman, J.T. (2009). Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood 113: 2805–2815.10.1182/blood-2008-05-159145Search in Google Scholar PubMed PubMed Central

Stein, E.M., DiNardo, C.D., Fathi, A.T., Pollyea, D.A., Stone, R.M., Altman, J.K., Roboz, G.J., Patel, M.R., Collins, R., Flinn, I.W., et al. (2019). Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 133: 676–687.10.1182/blood-2018-08-869008Search in Google Scholar PubMed PubMed Central

Stomper, J., Rotondo, J.C., Greve, G., and Lübbert, M. (2021). Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35: 1873–1889.10.1038/s41375-021-01218-0Search in Google Scholar PubMed PubMed Central

Stone, R.M., Mandrekar, S.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede, C., Prior, T.W., Döhner, K., Marcucci, G., et al. (2017). Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377: 454–464.10.1056/NEJMoa1614359Search in Google Scholar PubMed PubMed Central

Tiong, I.S., Dillon, R., Ivey, A., Teh, T.C., Nguyen, P., Cummings, N., Taussig, D.C., Latif, A.L., Potter, N.E., Runglall, M., et al. (2021). Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br. J. Haematol. 192: 1026–1030.10.1111/bjh.16722Search in Google Scholar PubMed PubMed Central

Tsao, T., Shi, Y., Kornblau, S., Lu, H., Konoplev, S., Antony, A., Ruvolo, V., Qiu, Y.H., Zhang, N., Coombes, K.R., et al. (2012). Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann. Hematol. 91: 1861–1870.10.1007/s00277-012-1537-8Search in Google Scholar PubMed PubMed Central

Tsujimoto, Y., Cossman, J., Jaffe, E., and Croce, C.M. (1985). Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440–1443.10.1126/science.3874430Search in Google Scholar PubMed

Valentin, R., Grabow, S., and Davids, M.S. (2018). The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood 132: 1248–1264.10.1182/blood-2018-02-791350Search in Google Scholar PubMed

Vogelmeier, C.F. (2016). Genomic classification in acute myeloid leukemia. N. Engl. J. Med. 375: 900–901.10.1056/NEJMc1608739Search in Google Scholar PubMed

Wei, A.H., Strickland, S.A., Hou, J.Z., Fiedler, W., Lin, T.L., Walter, R.B., Enjeti, A., Tiong, I.S., Savona, M., Lee, S., et al. (2019). Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J. Clin. Oncol. 37: 1277–1284.10.1200/JCO.18.01600Search in Google Scholar PubMed PubMed Central

Wei, A.H., Montesinos, P., Ivanov, V., DiNardo, C.D., Novak, J., Laribi, K., Kim, I., Stevens, D.A., Fiedler, W., Pagoni, M., et al. (2020). Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135: 2137–2145.10.1182/blood.2020004856Search in Google Scholar PubMed PubMed Central

Welch, J.S., Petti, A.A., Miller, C.A., Fronick, C.C., O’Laughlin, M., Fulton, R.S., Wilson, R.K., Baty, J.D., Duncavage, E.J., Tandon, B., et al. (2016). TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N. Engl. J. Med. 375: 2023–2036.10.1056/NEJMoa1605949Search in Google Scholar PubMed PubMed Central

Yilmaz, M., Kantarjian, H.M., Muftuoglu, M., Kadia, T.M., Konopleva, M., Borthakur, G., DiNardo, C.D., Pemmaraju, N., Short, N.J., Alvarado, Y., et al. (2020). Quizartinib with decitabine +/- venetoclax is highly active in patients (pts) with FLT3-ITD mutated (mut) acute myeloid leukemia (AML): clinical report and signaling cytof profiling from a phase IB/II trial. Am. J. Hematol. 616: 26.10.1182/blood-2020-142687Search in Google Scholar

Zeidan, A.M., Wang, R., Wang, X., Shallis, R.M., Podoltsev, N.A., Bewersdorf, J.P., Huntington, S.F., Neparidze, N., Giri, S., Gore, S.D., et al. (2020). Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 4: 2192–2201.10.1182/bloodadvances.2020001779Search in Google Scholar PubMed PubMed Central

Zhu, R., Li, L., Nguyen, B., Seo, J., Wu, M., Seale, T., Levis, M., Duffield, A., Hu, Y., and Small, D. (2021). FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation. Signal Transduct. Target Ther. 6: 186.10.1038/s41392-021-00578-4Search in Google Scholar PubMed PubMed Central